Search Within

Sarat Chandarlapaty

  1. "Qing Ye"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (3)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  2. Breast Medicine Service (8)
  3. Department of Medicine (8)
  4. GSK Faculty (8)
  5. Human Oncology and Pathogenesis Program (8)
  6. Molecular Pharmacology and Chemistry Program Faculty (8)

More Groups

People
  1. Neal Rosen (8)
  2. Qing Ye (8)
  3. David Solit (4)
  4. Qing-Bai She (4)
  5. Jose Lobo (3)
  6. Ayana Sawai (2)

More People

Years
  1. 2010 (1)
  2. 2009 (2)
  3. 2008 (3)
  4. 2007 (1)
  5. 2006 (1)
Publications
  1. Cancer Research (4)
  2. Clinical Cancer Research (1)
  3. EJC Supplements (1)
  4. Journal of Clinical Oncology (1)
  5. PLoS ONE (1)
Publishers
  1. American Association for Cancer Research (5)
  2. American Society of Clinical Oncology (1)
  3. Pergamon-Elsevier Science Ltd (1)
  4. Public Library of Science (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • AZD8055 is an effective inhibitor of mTOR kinase signaling and breast cancer growth while relieving feedback inhibition of HER-kinase signaling
    Meeting Abstract

    Rodrik - Outmezguine, V. S.; Cao, N.; Chandarlapaty, S.; She, Q. B.; Ye, Q.; Smith, P.; Guichard, S.; Rosen, N.
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Breast tumor cells with PI3K mutation or HER2 amplification are selectively dependent on Akt signaling
    Meeting Abstract

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K.; Leander, K.; DeFeo-Jones, D.; Huber, H.; Rosen, N.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling
    Meeting Abstract

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Breast tumor cells with P13K mutation or HER2 amplification are selectively addicted to Akt signaling
    Journal Article

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    PLoS ONE (2008)

    Fulltext@MSK | Save
  • Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
    Journal Article

    Sawai, A.; Chandarlapaty, S.; Greulich, H.; Gonen, M.; Ye, Q.; Arteaga, C. L.; Sellers, W.; Rosen, N.; Solit, D. B.
    Cancer Research (2008)

    Fulltext@MSK | Save
  • SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase - Dependent cancers
    Journal Article

    Chandarlapaty, S.; Sawai, A.; Ye, Q.; Scott, A.; Silinski, M.; Huang, K.; Fadden, P.; Partdrige, J.; Hall, S.; Steed, P.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Baselga, J.; Ye, Q.; Solit, D.; Norton, L.; Rosen, N.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • SNX5542, an oral Hsp90 inhibitor, causes Her2 degradation and inhibition of tumor growth in models of Her2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Ye, Q.; Huang, K.; Fadden, P.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save